grapiprant: Clinical Trials

4 trials of grapiprant, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 terminated. 4 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Completed 2, Terminated 2
Phase 22Terminated 2

Follow grapiprant: new trials by email Literature Review of grapiprant trials Research Report on grapiprant

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
Eribulin Mesylate, Grapiprant - Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center62021-12-212025-06-13
Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma
grapiprant and pembrolizumab - Non-small Cell Lung Cancer Adenocarcinoma
Phase 1 / Phase 2TerminatedArrys Therapeutics182019-01-082021-02-21
Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer
grapiprant, grapiprant and pembrolizumab - Microsatellite Stable Colorectal Cancer
Phase 1CompletedArrys Therapeutics542018-09-202023-10-24
A Study Of The Effect Of CJ-023,423 On The Incidence Of Stomach Ulcers
CJ-023,423, placebo, naproxen - Osteoarthritis
Phase 1CompletedPfizer3402006-11-012008-03-24

Conditions studied

Inflammatory Breast Neoplasms (1)  ·  Osteoarthritis (1)

Sponsors

Arrys Therapeutics (2)  ·  M.D. Anderson Cancer Center (1)  ·  Pfizer (1)

Countries

United States (4)

Top investigators

Jason Sager, MD (1)  ·  Sadia Saleem (1)  ·  Sergio Santillana, MD (1)

Results publications

PMID 34606846